Ambrx Biopharma Cayman, Inc. Quarterly Operating Income (Loss) in USD from Q1 2022 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ambrx Biopharma Cayman, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2022 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$19.2M, a 33.4% increase year-over-year.
  • Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2022 was -$76.4M, a 18.6% decline from 2021.
  • Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2021 was -$64.4M, a 391% decline from 2020.
  • Ambrx Biopharma Cayman, Inc. annual Operating Income (Loss) for 2020 was -$13.1M, a 41.6% increase from 2019.
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$19.2M +$9.61M +33.4% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 -$16M +$4.09M +20.3% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q2 2022 -$28.8M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$20.1M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.